

GLUL Antibody (N-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP6892A

Product Information

Application WB, IHC-P, E **Primary Accession** P15104

Other Accession P46410, P15105, Q4R7U3, P16580, P15103

Reactivity Human, Mouse, Rat

Predicted Monkey, Pig, Chicken, Bovine

HostRabbitClonalityPolyclonalIsotypeRabbit IgGClone NamesRB21070Calculated MW42064Antigen Region70-96

Additional Information

Gene ID 2752

Other Names Glutamine synthetase, GS, Glutamate decarboxylase, Glutamate--ammonia

ligase, GLUL, GLNS

Target/Specificity This GLUL antibody is generated from rabbits immunized with a KLH

conjugated synthetic peptide between 70-96 amino acids from the N-terminal

region of human GLUL.

Dilution WB~~1:1000 IHC-P~~1:100~500 E~~Use at an assay dependent concentration.

Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide.

This antibody is purified through a protein A column, followed by peptide

affinity purification.

Storage Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store

at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions GLUL Antibody (N-term) is for research use only and not for use in diagnostic

or therapeutic procedures.

Protein Information

Name GLUL {ECO:0000303|PubMed:30158707, ECO:0000312|HGNC:HGNC:4341}

Function Glutamine synthetase that catalyzes the ATP-dependent conversion of

glutamate and ammonia to glutamine (PubMed: 16267323,

PubMed:30158707, PubMed:36289327). Its role depends on tissue localization: in the brain, it regulates the levels of toxic ammonia and converts neurotoxic glutamate to harmless glutamine, whereas in the liver, it is one of the enzymes responsible for the removal of ammonia (By similarity). Plays a key role in ammonium detoxification during erythropoiesis: the glutamine synthetase activity is required to remove ammonium generated by porphobilinogen deaminase (HMBS) during heme biosynthesis to prevent ammonium accumulation and oxidative stress (By similarity). Essential for proliferation of fetal skin fibroblasts (PubMed: 18662667). Independently of its glutamine synthetase activity, required for endothelial cell migration during vascular development: acts by regulating membrane localization and activation of the GTPase RHOJ, possibly by promoting RHOJ palmitoylation (PubMed:30158707). May act as a palmitoyltransferase for RHOJ: able to autopalmitoylate and then transfer the palmitoyl group to RHOJ (PubMed:30158707). Plays a role in ribosomal 40S subunit biogenesis (PubMed:<u>26711351</u>). Through the interaction with BEST2, inhibits BEST2 channel activity by affecting the gating at the aperture in the absence of intracellular L-glutamate, but sensitizes BEST2 to intracellular L-glutamate, which promotes the opening of BEST2 and thus relieves its inhibitory effect on BEST2 (PubMed:36289327).

Cellular Location

Cytoplasm, cytosol. Microsome {ECO:0000250|UniProtKB:P09606} Mitochondrion {ECO:0000250|UniProtKB:P09606}. Cell membrane; Lipid-anchor. Note=Mainly localizes in the cytosol, with a fraction associated with the cell membrane

Tissue Location

Expressed in endothelial cells.


Background

GLUL belongs to the glutamine synthetase family. It catalyzes the synthesis of glutamine from glutamate and ammonia. Glutamine is a main source of energy and is involved in cell proliferation, inhibition of apoptosis, and cell signaling.

References


Di Tommaso, L., et.al., J. Hepatol. 50 (4), 746-754 (2009)

Images



Western blot analysis of GLUL Antibody (N-term) (Cat. #AP6892a) in mouse cerebellum tissue lysates (35ug/lane). GLUL (arrow) was detected using the purified Pab.

Formalin-fixed and paraffin-embedded human testis tissue reacted with GLUL Antibody (N-term), which was peroxidase-conjugated to the secondary antibody,



followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.